Vitrolife private equity investment committee paper - company valuation in the context of private equity

Abstract

Vitrolife is a leading provider of in-vitro fertilization products, offering medical Consumables, Technological devices, and Genetic Testing services across the entire IVF journey. It is an attractive target for a private equity fund, given its stable EBITDA margin, strong competitive position in a high-growth market and its in-house R&D capabilities. Value creation is driven through three strategies: Eastern Europe market penetration, AI-Partnership and forward integration through the acquisition of Virtus Health. Based on an estimated exit multiple of 16.7x EBITDA, investors are expected to receive a 3.6x MM return over a six-year holding period.